{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:31:32Z","timestamp":1790389892819,"version":"4.1.0"},"reference-count":43,"publisher":"Informa UK Limited","issue":"32","funder":[{"name":"AstraZeneca"},{"name":"Roche"},{"name":"Tesaro"},{"DOI":"10.13039\/501100013119","name":"Pharmamar","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013119","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Clovis"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2019,11,30]]},"DOI":"10.2217\/fon-2019-0343","type":"journal-article","created":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T09:03:07Z","timestamp":1569402187000},"page":"3651-3663","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":13,"title":["Olaparib Maintenance Monotherapy in Platinum-Sensitive, Relapsed Ovarian Cancer Without Germline\n                    <i>BRCA<\/i>\n                    Mutations: OPINION Phase IIIb Study Design"],"prefix":"10.1080","volume":"15","author":[{"given":"Andres M","family":"Poveda","sequence":"first","affiliation":[{"name":"Department of Gynecologic Oncology, Initia Oncology, 46010Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Davidson","sequence":"additional","affiliation":[{"name":"GMA Oncology TA, AstraZeneca, Cambridge, CB2 8PA, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Blakeley","sequence":"additional","affiliation":[{"name":"GMA Oncology TA, AstraZeneca, Cambridge, CB2 8PA, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvin","family":"Milner","sequence":"additional","affiliation":[{"name":"Biometrics&amp;Information Sciences, AstraZeneca, Cambridge, CB2 8PA, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2019,9,25]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.12.027"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21208"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt333"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.08.004"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.307"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105535"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611310"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30469-2"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds203"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2015.10.040"},{"key":"e_1_3_3_13_1","unstructured":"EMA . Lynparza (olaparib) summary of product characteristics (2018). &ext-link ext-link-type=\"uri\" xlink:href=\"http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/003726\/human_med_001831.jsp;WC0b01ac058001d124\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\">www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/003726\/human_med_001831.jsp;mid=WC0b01ac058001d124."},{"key":"e_1_3_3_14_1","unstructured":"AstraZeneca Pharmaceuticals LP . Lynparza\u00ae prescribing information DE USA (2018).www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/208558s006lbl.pdf"},{"key":"e_1_3_3_15_1","unstructured":"AstraZeneca . Lynparza approved in the EU for 1st-line maintenance treatment of BRCA-mutated advanced ovarian cancer (2019). www.astrazeneca.com\/media-centre\/press-releases\/2019\/lynparza-approved-in-the-eu-for-1st-line-maintenance-treatment-of-brca-mutated-advanced-ovarian-cancer-18062019.html"},{"key":"e_1_3_3_16_1","unstructured":"AstraZeneca . Lynparza approved in Japan for 1st-line maintenance therapy in BRCA-mutated advanced ovarian cancer (2019). www.astrazeneca.com\/media-centre\/press-releases\/2019\/lynparza-approved-in-japan-for-1st-line-maintenance-therapy-in-brca-mutated-advanced-ovarian-cancer-19062019.html"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0485"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0271-y"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70228-1"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32440-6"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10166"},{"key":"e_1_3_3_22_1","unstructured":"Myriad . myChoice\u00ae HRD\u2122 (2018). https:\/\/myriad.com\/products-services\/companion-diagnostics\/mychoice-hrd\/"},{"key":"e_1_3_3_23_1","unstructured":"Foundation Medicine . FoundationFocus\u2122 CDxBRCA LOH (2018). www.accessdata.fda.gov\/cdrh_docs\/pdf16\/P160018S001c.pdf"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0274-8"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc4019"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-2287"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-018-3532-9"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.41"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.9589"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.08.022"},{"issue":"6","key":"e_1_3_3_31_1","first-page":"856O","article-title":"Clinical activity of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC) and a BRCA mutation (BRCAmut): analysis of pooled data from study 10 (parts 1, 2a, and 3) and ARIEL2 (parts 1 and 2)","volume":"27","author":"Kristeleit R","year":"2016","unstructured":"Kristeleit R , Shapira-FrommerR, OakninAet al. Clinical activity of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC) and a BRCA mutation (BRCAmut): analysis of pooled data from study 10 (parts 1, 2a, and 3) and ARIEL2 (parts 1 and 2). Ann. Oncol.27(Suppl. 6), 856O (2016).","journal-title":"Ann. Oncol."},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29082"},{"key":"e_1_3_3_33_1","unstructured":"FACIT . FACIT measurement system questionnaires (2010). www.facit.org\/facitorg\/questionnaires"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x"},{"key":"e_1_3_3_35_1","unstructured":"Myriad . BRACAnalysis\u00ae (2019). https:\/\/myriad.com\/products-services\/hereditary-cancers\/bracanalysis\/"},{"key":"e_1_3_3_36_1","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: ovarian cancer version 2 (2018). www.nccn.org\/professionals\/physician_gls\/pdf\/ovarian.pdf"},{"key":"e_1_3_3_37_1","unstructured":"US FDA . Lynparza prescribing information (2017 update) (2014). www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208558s000lbl.pdf"},{"key":"e_1_3_3_38_1","unstructured":"AstraZeneca . Lynparza tablets receive EU approval for the treatment of platinum-sensitive relapsed ovarian cancer (2018). www.astrazeneca.com\/content\/astraz\/media-centre\/press-releases\/2018\/lynparza-tablets-receive-eu-approval-for-the-treatment-of-platinum-sensitive-relapsed-ovarian-cancer08052018.html"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2014.08.004"},{"key":"e_1_3_3_40_1","unstructured":"AstraZeneca. To assess the efficacy and safety of olaparib maintenance monotherapy in the treatment of ovarian cancer (ORZORA).Identifier: NCT02476968 (2018). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02476968"},{"key":"e_1_3_3_41_1","unstructured":"AstraZeneca. Olaparib tablets as a treatment for ovarian cancer subjects with different HRD tumor status. Identifier: NCT02983799. (2019). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02983799"},{"key":"e_1_3_3_42_1","unstructured":"AstraZeneca. Olaparib tablets maintenance monotherapy ovarian cancer patients after complete or partial response to platinum chemotherapy (L-MOCA). (2018). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03534453"},{"key":"e_1_3_3_43_1","unstructured":"AstraZeneca. Platine Avastin and OLAparib in 1st line (PAOLA-1). Identifier: NCT02477644 (2016). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02477644"},{"key":"e_1_3_3_44_1","unstructured":"AstraZeneca. A study to examine olaparib maintenance retreatment in patients with epithelial ovarian cancer (OReO) (2017). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03106987"},{"key":"e_1_3_3_45_1","unstructured":"AstraZeneca. Study evaluating the efficacy of maintenance olaparib and cediranib or olaparib alone in ovarian cancer patients (ICON9) (2017). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03278717"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2019-0343","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T02:45:36Z","timestamp":1719110736000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2019-0343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,25]]},"references-count":43,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2019,11,30]]}},"alternative-id":["10.2217\/fon-2019-0343"],"URL":"https:\/\/doi.org\/10.2217\/fon-2019-0343","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,25]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-06-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}